The Board of Shell plc (the "Company") (XLON: SHEL, XNYS: SHEL, XAMS: SHELL) today announced an interim dividend in respect of the fourth quarter of 2024 of US$ 0.358 per ordinary share. Details ...

Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, ...

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as ...

Innovative structural color coatings from Chiba University combine hydrophobic melanin particles, offering long-lasting ...

Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that non-profit ...

NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...

In a step towards developing advanced materials for functional coatings, a research group from Japan, developed a technology ...

Takeda Pharmaceutical Co. will get to arbitrate claims by a plaintiff that accused the company of delaying the generic ...

Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel ...

FILE - Scottie Scheffler gestures on the 18th green at Pebble Beach Golf Links during the third round of the AT&T Pebble ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.